Zentalis Pharmaceuticals (ZNTL)
(Delayed Data from NSDQ)
$1.52 USD
+0.03 (2.01%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $1.54 +0.02 (1.32%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
Fundamental Charts
About Return on Equity (TTM)
Zentalis Pharmaceuticals, Inc.'s return on equity, or ROE, is -51.62% compared to the ROE of the Medical - Biomedical and Genetics industry of -66.95%. While this shows that ZNTL has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
ZNTL 1.52 +0.03(2.01%)
Will ZNTL be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ZNTL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ZNTL
Zentalis Pharmaceuticals (ZNTL) Loses -46.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Zentalis Pharmaceuticals (ZNTL) Upgraded to Strong Buy: What Does It Mean for the Stock?
ZNTL: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Buy Stocks for January 9th
Other News for ZNTL
Is ZNTL ready to move higher? Pocket Pivot shows up after climbing 2.01%
Stochastic Buy Signal appears for ZNTL after 4.93% move
The technical outlook for ZNTL is unchanged after sideways trading on September 17
H.C. Wainwright Remains a Buy on Zentalis Pharmaceuticals (ZNTL)
New Downtrend appears for ZNTL after 2.07% move